Efficacy and Safety of Tofacitinib in Psoriatic Arthritis: Comparator Study

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Tofacitinib (CP-690,550) or Adalimumab in Subjects With Active Psoriatic Arthritis

Category & Conditions:
Immune System Diseases and Conditions
Medicine:
XELJANZ®(TOFACITINIB)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
A3921091
Open Plain Language Summary Result:Click here